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average total episode costs were found in the Northeast region
and were $856.50. Average outpatient costs in the Northeast
region were the highest in the country at $377.64—the range for
other regions was $240.70-$285.93. CONCLUSION: Much
diversity exists in the cost of treating acne across different seg-
ments of the United States. Future research should be done to
determine what the underlying factors are when accounting for
the discrepancies in cost per episode of acne.
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OBJECTIVE: To determine the most cost-effective Wet AMD
treatment alternative in Mexico. METHODS: A decision tree
with Bayesian approach and a Markov chain considering the
probabilities of increasing, decreasing or maintaining visual
acuity (VA) through eight health states based on VA from 20/20
to 20/400 due to the use of a pharmacological alternative, with a
time horizon of 5 years and institutional perspective, were per-
formed. The discounting rate was three percent for costs and
beneﬁts. Adverse events and their treatment costs, for every
alternative were considered; costs, beneﬁts and probabilities of
transition data were estimated from the meta-analysis with avail-
able published literature, including the MARINA and ANCHOR
studies, validated by a panel of Mexican experts through the
Delphi technique. Study comparators examined were Ranibi-
zumab (RAN), photodynamic therapy with Verteporﬁn (PDTV),
pegaptanib sodium (PEG) and standard care (STD). Sensitivity
analysis was one-way and probabilistic (acceptability curve,
analysis of components for the ellipse method). RESULTS:
Patients using Ranibizumab get more beneﬁts (RAN = 2.71
QALY; PDTV = 2.03 QALY; PEG = 1.89 QALY; STD = 1.78
QALY), with the lowest total cost per treatment (RAN =
$43,984 USD; STD = $63,531 USD; PDTV = $83,546 USD;
PEG = $92,247 USD) and the lowest cost per QALY (RAN =
$16,257 USD/QALY; STD = $35,749 USD/QALY; PDTV =
$41,074 USD/QALY; PEG = $48,263 USD/QALY). Incremental
analysis showed Ranibizumab to be the dominant alternative.
Net beneﬁts are greater with Ranibizumab independent of will-
ingness to pay. Acceptability curves showed absolute superiority
for Ranibizumab. The conﬁdence interval of 95% with the ellipse
method showed Ranibizumab to be dominant in 95% of the
cases with a willingness to pay of $924USD. The sensitivity
analysis on efﬁciency and costs of Ranibizumab in an interval of
50%, was robust with the base analysis. CONCLUSION:
Ranibizumab is the most cost-effective Wet AMD treatment
alternative; it offers the greatest beneﬁts with the lowest cost.
Sensitivity analyses showed the robustness of the base study.
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OBJECTIVE: Measure incremental cost-utility and budget
impact of etanercept vs. inﬂiximab in moderate-to-severe PSO
with >10% body surface area involvement. METHODS: We
used a Markov decision analysis to compare 2 strategies for PSO:
etanercept label dose (50 mg BIW x12 wks, then 25 mg BIW);
and inﬂiximab label dose (5 mg/kg IV at wks 0, 2, and 6, then
5mg/kg Q8W). We derived 60 probability estimates through
systematic review of the literature and labels, varying each of
these estimates in each sensitivity analysis. We adopted an MCO
payer’s perspective, and included cost estimates for a compre-
hensive list of related resources as determined by Medicare and
the Red Book. Qulaity-adjusted life-years (QALYs) were esti-
mated by applying utilities from the literature to reported efﬁcacy
as measured by PASI scores. We calculated the incremental cost
per QALY gained and incremental per-member per month
(PMPM) budget impact in a hypothetical MCO of 1 million lives
(assuming a 1% prevalence of moderate-to-severe PSO). We dis-
counted costs and effects at 3% per year over a 2-year time
horizon. RESULTS: In the base-case analysis, etanercept yielded
1.68 QALYs at a total cost of $28,442 over the 2-year horizon,
and inﬂiximab yielded 1.78 QALYs at a cost of $49,906. Com-
pared to etanercept, inﬂiximab cost an incremental $214,640/
QALY-gained. In sensitivity analysis, inﬂiximab dominated
etanercept when the cost of inﬂiximab fell by 55% (from $691 to
$312 per 100 mg vial), or when the cost of etanercept increased
83% (from $187 to $342 per 25 mg vial). In budget impact
modeling, inﬂiximab cost an incremental $8.94 PMPM vs. etan-
ercept. CONCLUSION: Decision analysis was used to model
relative cost-utility and budget impact of biologic therapies in
PSO—a chronic health condition. The incremental cost and
budget impact of inﬂiximab vs etanercept exceeds standard
benchmarks in the absence of comparative effectiveness from
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OBJECTIVE: To evaluate persistence among glaucoma patients
with prostaglandin therapy during the ﬁrst therapy year.
METHODS: Patients with latanoprost (LAT), bimatoprost
(BIM), or travoprost (TRAV) dispensed during January 1, 2004–
December 31, 2004 were screened for inclusion (Ingenix
managed care database). Index agent = ﬁrst agent ﬁlled; index
date = ﬁll date; follow-up = 358 days. Patients excluded if:
age < 40 years; not continuously enrolled for 180 days before/
358 days after index date; had ocular hypotensive dispensed or
had no glaucoma diagnosis within 180 days before index date.
First year persistence measures: whether last ﬁll had sufﬁcient
days supply to achieve medication possession at year’s end;
number of days for which index agent was available (days
covered). Possible inconsistencies between quantity dispensed
and reported days supply addressed by multiplying claimed days
supply with alternative measures from the literature. Models of
associations between index agent and medication possession
(logistic regression) and days covered (linear regression) were
adjusted for gender, age, and previous ocular hypertension diag-
nosis. RESULTS: A total of 7783 patients met inclusion criteria
(LAT, n = 4994; BIM, n = 1464; TRAV, n = 1415). Overall medi-
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